Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y689
UPID:
ARL5A_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y689; Q580I5
Background:
ADP-ribosylation factor-like protein 5A, identified by the accession number Q9Y689, plays a unique role in cellular processes due to its distinct lack of ADP-ribosylation enhancing activity. This characteristic sets it apart from other proteins within its family, highlighting its potential for specialized functions in cellular mechanisms.
Therapeutic significance:
Understanding the role of ADP-ribosylation factor-like protein 5A could open doors to potential therapeutic strategies. Its unique functional profile suggests it may be a key player in pathways yet to be fully understood, offering new avenues for drug discovery.